The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  AJP - Renal Physiology

• Publication date

  2014-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/ajprenal.00604.2013PMID 24598801
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Noncanonical Control of Vasopressin Receptor Type 2 Signaling by Retromer and Arrestin*

  2013cited by this paper
• A Historical Survey

  2013cited by this paper
• Temporal delays and individual variation in antidiuretic response to desmopressin.

  2013cited by this paper
• Vasopressin inhibits apoptosis in renal collecting duct cells.

  2013cited by this paper
• Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo‐controlled trial

  2013cited by this paper
• Long‐term durability of the response to desmopressin in female and male nocturia patients

  2013cited by this paper
• Identifying protein kinase target preferences using mass spectrometry.

  2012cited by this paper
• AGONIST OF V2 VASOPRESSIN RECEPTOR REDUCES DEPRESSIVE DISORDERS IN POST-STROKE PATIENTS

  2012cited by this paper
• Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation

  2012cited by this paper
• Tolvaptan in patients with autosomal dominant polycystic kidney disease.

  2012cited by this paper
• [Agonist of V2 vasopressin receptor reduces depressive disorders in post-stroke patients].

  2012cited by this paper
• Localization of aquaporins 1, 2, and 3 and vasopressin type 2 receptor in the mouse inner ear

  2012cited by this paper
• Collecting duct cells that lack normal cilia have mislocalized vasopressin-2 receptors.

  2012cited by this paper
• Plasma corticotrophin response to desmopressin in patients with Cushing’s disease correlates with the expression of vasopressin receptor 2, but not with that of vasopressin receptor 1 or 3, in their pituitary tumours

  2012cited by this paper
• Calmodulin-sensitive adenylyl cyclases mediate AVP-dependent cAMP production and Cl- secretion by human autosomal dominant polycystic kidney cells.

  2012cited by this paper
• Desmopressin orally disintegrating tablet effectively reduces nocturia: Results of a randomized, double‐blind, placebo‐controlled trial

  2012cited by this paper
• Genetics and diagnosis of central diabetes insipidus.

  2012cited by this paper
• Cell biology of vasopressin-regulated aquaporin-2 trafficking

  2012cited by this paper
• Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.

  2011cited by this paper
• Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells.

  2011cited by this paper
• Age‐dependent skewing of X chromosome inactivation appears delayed in centenarians’ offspring. Is there a role for allelic imbalance in Healthy Aging and Longevity?

  2011cited by this paper
• Genes that escape from X inactivation

  2011cited by this paper
• Sex differences in vasopressin V₂ receptor expression and vasopressin-induced antidiuresis.

  2011cited by this paper
• Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis.

  2011cited by this paper
• Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.

  2011cited by this paper
• Arginine vasopressin controls p27(Kip1) protein expression by PKC activation and irreversibly inhibits the proliferation of K-Ras-dependent mouse Y1 adrenocortical malignant cells.

  2011cited by this paper
• Expression and Translocation of Aquaporin‐2 in the Endolymphatic Sac in Patients with Meniere’s Disease

  2010cited by this paper
• Arginine-Vasopressin V1 but not V2 Receptor Antagonism Modulates Infarct Volume, Brain Water Content, and Aquaporin-4 Expression Following Experimental Stroke

  2010cited by this paper
• Hormonal Aspects of Ménière’s Disease on the Basis of Clinical and Experimental Studies

  2010cited by this paper
• THE METABOLIC AND MOLECULAR BASES OF INHERITED DISEASE

  2010cited by this paper
• Functional variation in the arginine vasopressin 2 receptor as a modifier of human plasma von Willebrand factor levels

  2010cited by this paper
• A study of variations in the reported haemophilia A prevalence around the world

  2010cited by this paper
• Towards a knowledge-based Human Protein Atlas

  2010cited by this paper
• Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension?

  2010cited by this paper
• Diagnosis and quantification of factor VIII inhibitors

  2009cited by this paper
• Correlation between tumor volume response to radiotherapy and expression of biological markers in patients with cervical squamous cell carcinoma.

  2009cited by this paper
• Sustained elevated levels of circulating vasopressin selectively stimulate the proliferation of kidney tubular cells via the activation of V2 receptors.

  2009cited by this paper
• V2R mutations and nephrogenic diabetes insipidus.

  2009influential reference
• Vasopressin: behavioral roles of an "original" neuropeptide.

  2008cited by this paper
• Oxytocin, Vasopressin, and the Neurogenetics of Sociality

  2008cited by this paper
• A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies*

  2008cited by this paper
• Vasopressin decreases sepsis-induced pulmonary inflammation through the V2R.

  2008cited by this paper
• Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

  2008cited by this paper
• Akt and ERK1/2 pathways are components of the vasopressin signaling network in rat native IMCD.

  2008cited by this paper
• X inactivation, female mosaicism, and sex differences in renal diseases.

  2008cited by this paper
• Anatomical profiling of G protein-coupled receptor expression.

  2008cited by this paper
• The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling.

  2007cited by this paper
• Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL.

  2007cited by this paper
• Psychophysiological Analysis of the Influence of Vasopressin on Speech in Patients with Post-Stroke Aphasias

  2007cited by this paper
• Expressions of Aquaporin‐2, Vasopressin Type 2 Receptor, Transient Receptor Potential Channel Vanilloid (TRPV)1, and TRPV4 in the Human Endolymphatic Sac

  2007cited by this paper
• Heritable skewed X-chromosome inactivation leads to haemophilia A expression in heterozygous females

  2007cited by this paper
• Role of vasopressin in rat distal colon function

  2007cited by this paper
• Trafficking of G Protein–Coupled Receptors

  2006cited by this paper
• Regulated release of VWF and FVIII and the biologic implications

  2006cited by this paper
• Provasopressin expression by breast cancer cells: implications for growth and novel treatment strategies

  2006cited by this paper
• Urea transporter UT-A1 and aquaporin-2 proteins decrease in response to angiotensin II or norepinephrine-induced acute hypertension.

  2006cited by this paper
• The central vasopressinergic system: examining the opportunities for psychiatric drug development.

  2005cited by this paper
• Oxytocin receptor pattern of expression in primary lung cancer and in normal human lung.

  2005cited by this paper
• Twin study of genetic and aging effects on X chromosome inactivation

  2005cited by this paper
• Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans.

  2005cited by this paper
• The hydrophobic amino acid residues in the membrane‐proximal C tail of the G protein‐coupled vasopressin V2 receptor are necessary for transport‐competent receptor folding

  2005cited by this paper
• X-inactivation profile reveals extensive variability in X-linked gene expression in females

  2005cited by this paper
• Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: involvement of a lysosomal degradation pathway.

  2005cited by this paper
• Non-muscle Myosin II and Myosin Light Chain Kinase Are Downstream Targets for Vasopressin Signaling in the Renal Collecting Duct*

  2004cited by this paper
• Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration.

  2004cited by this paper
• Surgical stress‐induced transient nephrogenic diabetes insipidus (NDI) associated with decreased Vasopressin receptor2 (AVPR2) expression linked to nonsense‐mediated mRNA decay and incomplete skewed X‐inactivation in a female patient with a heterozygous AVPR2 mutation (c. 89–90 delAC)

  2004cited by this paper
• Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).

  2004cited by this paper
• Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor‐ and cAMP‐mediated signaling

  2003cited by this paper
• The effects of V2 antagonist (OPC-31260) on endolymphatic hydrops.

  2003cited by this paper
• Hypertonicity Is Involved in Redirecting the Aquaporin-2 Water Channel into the Basolateral, Instead of the Apical, Plasma Membrane of Renal Epithelial Cells*

  2003cited by this paper
• Coupling of vasopressin‐induced intracellular Ca2+ mobilization and apical exocytosis in perfused rat kidney collecting duct

  2002cited by this paper
• The effect of desmopressin on short-term memory in children with primary nocturnal enuresis.

  2001cited by this paper
• Escape from antidiuresis: a good story.

  2001cited by this paper
• Endolymphatic hydrops induced by chronic administration of vasopressin.

  2001cited by this paper
• Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.

  2000cited by this paper
• Endolymphatic hydrops induced by chronic administration of vasopressin.

  2000cited by this paper
• Regulation of Aquaporin-2 Trafficking by Vasopressin in the Renal Collecting Duct

  2000cited by this paper
• The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues

  2000cited by this paper
• Gene regulation of vasopressin and vasopressin receptors in cancer

  2000cited by this paper
• The mechanisms of aquaporin control in the renal collecting duct.

  2000cited by this paper
• V2-receptor-mediated relaxation of human renal arteries in response to desmopressin.

  1999cited by this paper
• O-Glycosylation of the V2 vasopressin receptor.

  1999cited by this paper
• Regulation of inner ear fluid in the rat by vasopressin.

  1999cited by this paper
• MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R.

  1999cited by this paper
• The effect of anti-diuretic hormone on the endolymphatic sac of the inner ear

  1998cited by this paper
• All three vasopressin receptor sub-types are expressed by small-cell carcinoma.

  1998cited by this paper
• Neuropsychological effects of vasopressin in healthy humans.

  1998cited by this paper
• Expression of mRNA encoding vasopressin V1a, vasopressin V2, and ANP-B receptors in the rat cochlea.

  1998cited by this paper
• Vasopressin receptors. A historical survey.

  1998cited by this paper
• Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide.

  1998cited by this paper
• β2-Adrenergic but not vasopressin V2 receptor mRNAs are expressed in the stria vascularis of the rat inner ear

  1998cited by this paper
• Effect of active fragments of arginine-vasopressin on the disturbance of spatial cognition in rats.

  1997cited by this paper
• Palmitoylation of the V 2 Vasopressin Receptor

  1997cited by this paper
• Palmitoylation of the V2 vasopressin receptor.

  1997cited by this paper
• X-chromosome inactivation in mammals.

  1997cited by this paper
• Effect of desmopressin on ACTH and cortisol secretion in states of ACTH excess

  1997cited by this paper
• Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared with depressive illness.

  1996cited by this paper
• Evidence for dual signaling pathways for V2 vasopressin receptor in rat inner medullary collecting duct.

  1996cited by this paper
• The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2.

  1996cited by this paper
• Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain.

  1995cited by this paper

• The neuropeptide in ischemic brain injury: insights, challenges, and horizon of targeted interventions.

  2026cites this paper
• Innovations in Targeting the V2 Receptor.

  2025cites this paper
• Discovery of Non-benzoazacyclic V2R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease.

  2025cites this paper
• The Lysosome Surface is an Unappreciated Hub for Vasopressin V2 Receptor Signaling

  2025cites this paper
• Pregnane X receptor (PXR) increases urine concentration by upregulating hypothalamic arginine vasopressin expression.

  2025cites this paper
• G protein-coupled receptor-mediated renal fibrosis: a key focus on kidney disease drug development

  2025cites this paper
• Mechanistic Insights into the Pathogenesis of Polycystic Kidney Disease

  2025cites this paper
• Identification of an Unexplored Dynamic Allosteric Site on the Activation Pathway of the Vasopressin V2 Receptor.

  2025cites this paper
• Kidney organoid models of Polycystic Kidney Disease - challenges and future directions.

  2025cites this paper
• Ciliary G-Protein Coupled Receptor Signaling in Polycystic Kidney Disease

  2025cites this paper
• Chronic Hyponatremia Potentiates Innate Anxiety-Like Behaviors Through the Dysfunction of Monoaminergic Neurons in Mice

  2025cites this paper
• Adenosine receptors activate cyclic adenosine monophosphate signaling in salivary gland cells

  2025cites this paper
• Non-peptidic natural products that target and modulate oxytocin and arginine vasopressin receptors: Opportunities and challenges.

  2025cites this paper
• Physiological basis of arginine vasopressin deficiency (AVP-D, formerly central diabetes insipidus) and AVP-resistance (AVP-R, formerly nephrogenic diabetes insipidus)

  2025cites this paper
• Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights

  2024cites this paper
• Oxytocin and vasopressin signaling in health and disease.

  2024cites this paper
• Oxytocin, the Love Hormone, in Stem Cell Differentiation

  2024cites this paper
• Copeptin as a diagnostic and prognostic biomarker in pediatric diseases

  2024cites this paper
• A novel AVPR2 gene mutation in a Chinese pedigree with nephrogenic diabetes insipidus

  2024cites this paper
• Nocturia in Menopausal Women: The Link Between Two Common Problems of the Middle Age

  2024cites this paper
• V2 vasopressin receptor mutations: future personalized therapy based on individual molecular biology

  2023cites this paper
• Argipressin-norepinephrine association in the treatment of septic shock: the use of the polydistrectual resistance index as an assessment of vascular compliance

  2023cites this paper
• Perioperative polyuria associated with dexmedetomidine administration during reconstruction breast surgery.

  2023cites this paper
• Early post-operative diabetes insipidus following resection of craniopharyngioma: Incidence and predictors

  2023cites this paper
• The Neurotrophic, Neuroprotective, Mitogenic, Antioxidant, and Antiapoptotic Properties of Vasopressin

  2023cites this paper
• メニエール病の病態・診断・治療 Update　動物モデル

  2023cites this paper
• The Role of Arginine-Vasopressin in Stroke and the Potential Use of Arginine-Vasopressin Type 1 Receptor Antagonists in Stroke Therapy: A Narrative Review

  2023cites this paper
• Pro‐haemostatic effect of DDAVP is partially derived through non‐classical (CD14dim /CD16 ++) monocytes residing the spleen

  2022cites this paper
• Vasopressin: a possible link between hypoxia and hypertension

  2022cites this paper
• Oxytocin, vasopressin, and social behavior: from neural circuits to clinical opportunities.

  2022cites this paper
• Kidney collecting duct cells make vasopressin in response to NaCl-induced hypertonicity

  2022influential citation
• Class A and C GPCR Dimers in Neurodegenerative Diseases

  2022cites this paper
• Exocrine scent marking: Coordinative role of arginine vasopressin in the systemic regulation of social signaling behaviors.

  2022cites this paper
• Endomembrane-Based Signaling by GPCRs and G-Proteins

  2022cites this paper
• Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones

  2022cites this paper
• A new Kunitz‐type snake toxin family associated with an original mode of interaction with the vasopressin 2 receptor

  2021cites this paper
• GPCRs: The most promiscuous druggable receptor of the mankind

  2021cites this paper
• Prolactin and Other Pituitary Disorders in Kidney Disease.

  2021cites this paper
• Therapeutic advances in ADPKD: the future awaits

  2021cites this paper
• Hyponatrémies en réanimation

  2021cites this paper
• Codonopsis Radix modulates water and electrolytes homeostasis in mice

  2021cites this paper
• Cardiovascular Neuroendocrinology: Emerging Role for Neurohypophyseal Hormones in Pathophysiology.

  2021cites this paper
• Signal transduction in primary cilia - analyzing and manipulating GPCR and second messenger signaling.

  2021cites this paper
• The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease.

  2021cites this paper
• Considering Sex as a Biological Variable in Basic and Clinical Studies: An Endocrine Society Scientific Statement.

  2021cites this paper
• The Biology of Vasopressin

  2021cites this paper
• Cryo-EM structure of the AVP–vasopressin receptor 2–Gs signaling complex

  2021cites this paper
• Clinical and Functional Characterization of a Novel Mutation in AVPR2 Causing Nephrogenic Diabetes Insipidus in a Four-Generation Chinese Family

  2021cites this paper
• Iponatriemie in terapia intensiva

  2021cites this paper
• Hiponatremia en cuidados intensivos

  2021cites this paper
• Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation

  2021cites this paper
• Vasopressin Receptors in Blood Vessels and Proliferation of Endotheliocytes

  2021cites this paper
• Vaptans or voluntary increased hydration to protect the kidney: how do they compare?

  2021cites this paper
• Intraoperative dexmedetomidine-induced polyuria from a loading dose: a case report

  2020cites this paper
• A possible mechanism of the formation of endolymphatic hydrops and its associated inner ear disorders.

  2020cites this paper
• Vasopressin receptor subtypes and renal sodium transport.

  2020cites this paper
• The role of vasopressin V1A and oxytocin OTR receptors in protective effects of arginine vasopressin against H2O2-induced oxidative stress in H9C2 cells

  2020cites this paper
• Development and therapeutic potential of vasopressin synthetic analog [V4Q5]dDAVP as a novel anticancer agent.

  2020cites this paper
• Administration of the vasopressin analog desmopressin for the management of bleeding in rectal cancer patients: results of a phase I/II trial

  2020cites this paper
• Inner Ear Arginine Vasopressin-Vasopressin Receptor 2-Aquaporin 2 Signaling Pathway Is Involved in the Induction of Motion Sickness

  2020cites this paper
• Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

  2020cites this paper
• Differential Osteoprotegerin Kinetics after Stimulation with Desmopressin and Lipopolysaccharides In Vivo

  2020cites this paper
• Agonist-induced formation of unproductive receptor-G12 complexes

  2020cites this paper
• Vasopressin escape and memory impairment in a model of chronic syndrome of inappropriate secretion of antidiuretic hormone in mice.

  2020cites this paper
• AVPR1A distribution in the whole C57BL/6J mouse neonate

  2020cites this paper
• Increase in Intraoperative Urine Output During Tympanoplasty: A Retrospective Cohort Study.

  2020cites this paper
• Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study.

  2020cites this paper
• Development of a Testing Funnel for Identification of Small-Molecule Modulators Targeting Secretin Receptors

  2020cites this paper
• A NOVEL INTRAGENIC DELETION RELATED TO THE ARGININE VASOPRESSIN V2 RECEPTOR CAUSES NEPHROGENIC DIABETES INSIPIDUS.

  2020cites this paper
• Otorhinolaryngological adverse effects of urological drugs

  2020cites this paper
• Inner ear AVP-V2R-AQP2 signaling pathway is involved in the induction of motion sickness

  2020cites this paper
• Central Diabetes Insipidus in a Patient with Stiff Person Syndrome

  2019cites this paper
• Other Pituitary Disorders and Kidney Disease

  2019cites this paper
• Osmoregulation Performance and Kidney Transplant Outcome.

  2019cites this paper
• Pathophysiologic Mechanisms of Nocturia and Nocturnal Polyuria: The Contribution of Cellular Function, the Urinary Bladder Urothelium, and Circadian Rhythm.

  2019cites this paper
• The contribution of collecting duct NOS1 to the concentrating mechanisms in male and female mice.

  2019cites this paper
• A huge cavity in the right upper abdomen.

  2019cites this paper
• Generalized tonic-clonic seizure in recent polytrauma: a case of severe hyponatraemia.

  2019cites this paper
• Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V2 receptor‐independent pathway

  2019cites this paper
• Vasopressin in Vasodilatory Shock.

  2019cites this paper
• Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial

  2019cites this paper
• Exogenous vasopressin dose-dependently modulates gastric microcirculatory oxygenation in dogs via V1A receptor

  2019cites this paper
• Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes

  2019cites this paper
• A novel AVPR2 missense mutation in an Asian family with inherited nephrogenic diabetes insipidus

  2019cites this paper
• Management of autosomal-dominant polycystic kidney disease—state-of-the-art

  2018cites this paper
• Managing nocturia: The multidisciplinary approach.

  2018cites this paper
• Altered expression of Aquaporin‐2 in one‐kidney, one‐clip hypertension

  2018cites this paper
• A Novel Mutation in the AVPR2 Gene Causing Congenital Nephrogenic Diabetes Insipidus

  2018cites this paper
• Effect of Chronic Kidney Disease on Changes in Vasopressin System Expression in the Kidney Cortex in Rats with Nephrectomy

  2018cites this paper
• Water and Sodium Balance

  2018cites this paper
• Desmopressin and nocturnal voiding dysfunction: Clinical evidence and safety profile in the treatment of nocturia

  2018cites this paper
• Polyuria‐polydipsia syndrome: a diagnostic challenge

  2018cites this paper
• Desmopressin-Induced Severe Hyponatremia with Central Pontine Myelinolysis: A Case Report

  2018cites this paper
• OP-NDTP180105 2..13

  2018cites this paper
• Two ancient neuropeptides, PACAP and AVP, modulate motivated behavior at synapses in the extrahypothalamic brain: a study in contrast

  2018cites this paper
• Prostaglandin E2 in the Regulation of Water Transport in Renal Collecting Ducts

  2017cites this paper
• Effects of arginine vasopressin on the urine proteome in rats

  2017cites this paper
• ARGININE VASOPRESSIN PROMOTES REDISTRIBUTION OF ADHESION JUNCTION PROTEIN E-CADHERIN IN KIDNEY EPITHELIAL CELLS

  2017cites this paper
• Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

  2017cites this paper
• Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders.

  2017cites this paper